Federal Research Institute of Pediatric Hematology, Oncology and Immunology
fnkc.ruLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
56
Active
17
Phase 3
18
Total enrollment
14,712
Pipeline matrix
Showing 20 of 20 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate | — | — | — | — | — | 1 | |
| Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine | — | — | — | — | — | 1 | |
| Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine | — | — | — | — | — | 1 | |
| Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 2 | |
| Ruxolitinib | — | — | — | — | 2 | ||
| Cyclosporine A | — | — | — | — | — | 1 | |
| monoclonal antibodies GD2 | — | — | — | — | — | 1 | |
| 4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine). | — | — | — | — | — | 1 | |
| Baricitinib | — | — | — | — | — | 1 | |
| Dinutuximab beta, temozolomide, irinotecan, autologous NK cell | — | — | — | — | — | 1 | |
| irinotecan, temozolomide, dinutuximab beta, NK-cell product | — | — | — | — | — | 1 | |
| Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 | — | — | — | — | — | 1 | |
| the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors. | — | — | — | — | — | 1 | |
| GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor | — | — | — | — | — | 1 | |
| Abatacept | — | — | — | — | 2 | ||
| Treosulfan | — | — | — | — | — | 3 | |
| Cyclophosphamide | — | — | — | — | — | 2 | |
| CD19/CD22 CAR-T | — | — | — | — | — | 1 | |
| Donor-derived Natural Killer Cell | — | — | — | — | — | 1 |
Next readouts
- 2022-03-13
- 2024-07-01
- 2024-08-15
- 2025-05-16
- 2026-07-10
- 2026-09-01
- 2026-10
- 2026-11-21
- 2026-12-15
- 2027-01-31
Top conditions
- Myelodysplastic Syndromes4
- Childhood Acute Lymphoblastic Leukemia3
- Wiskott-Aldrich Syndrome3
- Ganglioneuroblastoma3
- Acute Myeloid Leukemia3
- Nijmegen Breakage Syndrome3
- Acute Lymphoblastic Leukemia3
- Biphenotypic Acute Leukemia3
Frequently asked questions about Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- How many clinical trials does Federal Research Institute of Pediatric Hematology, Oncology and Immunology have on ClinicalTrials.gov?
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology is listed as the lead sponsor on 56 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Federal Research Institute of Pediatric Hematology, Oncology and Immunology's trials are in Phase 3?
- 18 of Federal Research Institute of Pediatric Hematology, Oncology and Immunology's trials are in Phase 3, spread across 20 active drug programs.
- What therapeutic areas does Federal Research Institute of Pediatric Hematology, Oncology and Immunology focus on?
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology's most-studied conditions on ClinicalTrials.gov are Myelodysplastic Syndromes, Childhood Acute Lymphoblastic Leukemia, Wiskott-Aldrich Syndrome, Ganglioneuroblastoma, Acute Myeloid Leukemia.
- When are Federal Research Institute of Pediatric Hematology, Oncology and Immunology's next clinical trial readouts?
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology has 10 upcoming primary-completion readouts tracked here; the soonest is “Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL”, expected around 2022-03-13.